Venclexta-Rituxan Combo Reduced Disease Progression in Relapsed CLL Patients in Phase 3 Trial
News
A combination of Venclexta (venetoclax) and Rituxan (rituximab) significantly reduces the risk of disease progression or death in relapsed or refractory chronic lymphocytic leukemia (CLL) patients, according to a Phase 3 clinical ... Read more